MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9551
-0.0175
-1.80%
After Hours: 0.9700 +0.0149 +1.56% 16:32 02/27 EST
OPEN
0.9500
PREV CLOSE
0.9726
HIGH
0.9955
LOW
0.9300
VOLUME
829.57K
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.7000
MARKET CAP
91.93M
P/E (TTM)
-1.3187
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SCYX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SCYX stock price target is 5.21 with a high estimate of 10.00 and a low estimate of 3.500.

EPS

SCYX News

More
  • Scynexis completes enrollment in second pivotal study of ibrexafungerp
  • Seeking Alpha - Article · 02/13 15:20
  • SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
  • PR Newswire · 02/13 13:08
  • Scynexis: A Promising Infectious Diseases Player For 2020
  • Seeking Alpha - Article · 01/13 18:50
  • Will SCYNEXIS Continue to Surge Higher?
  • Zacks · 01/09 12:05

Industry

Pharmaceuticals
-2.78%
Pharmaceuticals & Medical Research
-3.00%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About SCYX

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
More

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.